ACLA Sues FDA Over Regulation of Laboratory-Developed Tests—in Texas
The choice of venue was likely inspired by the longstanding anti-regulatory stance of the state's federal judges.
The choice of venue was likely inspired by the longstanding anti-regulatory stance of the state's federal judges.
It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.
In a move to expand access to lab testing for monkeypox, HHS has authorized the FDA to issue EUAs for in vitro diagnostic tests for the virus.
On August 21, the FDA proposed new guidelines on charging for investigational drugs; here are the key highlights.
Revised final rule essentially disarms the threat of insurers having the advantage in out-of-network price disputes.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.
In a surprise move, the e-retail giant announced it will close down its Amazon Care Primary Health Services for employees at the end of 2022.
While not nearly as robust as a year ago, diagnostic companies’ revenues held up surprisingly well in Q2 2022.
Completing the Advance Beneficiary Notice of Noncoverage form can be extremely complex; this guide helps simplify the process.
In this Labs in Court monthly roundup, the Texas-based pathology lab was accused of falsely billing Medicare for unnecessary tests on biopsy specimens.
How much, if any, should a whistleblower get of what the government recovers in criminal or related legal actions resulting from a qui tam suit?